OBJECTIVE: In this study, we investigated whether FDG-PET/CT parameters were associated with a change in the quality of life (QoL) in patients with ILD over 4 years of follow-up.
METHODS: Patients underwent PET-CT imaging at diagnosis and were followed up with annual QoL assessment using the St George\'s Respiratory Questionnaire (SGRQ) until death or 4 years of follow-up. Maximum standard uptake value (SUVmax) and Tissue-to-Background Ratio (TBR) were assessed against SGRQ overall and subscale scores.
RESULTS: 193 patients (94 patients in the idiopathic pulmonary fibrosis (IPF) subgroup and 99 patients in the non-IPF subgroup) underwent baseline FDG-PET/CT imaging and QoL assessment. Weak-to-moderate correlation was observed between baseline SUVmax and SGRQ scores in both ILD subgroups. No relationship was observed between baseline SUVmax or TBR and change in SGRQ scores over 4 years of follow-up. In the IPF subgroup, surviving patients reported a decline in QoL at 4 years post diagnosis whereas an improvement in QoL was seen in surviving patients with non-IPF ILD.
CONCLUSIONS: Weak-to-moderate positive correlation between baseline SUVmax and SGRQ scores was observed in both ILD subgroups (IPF:rs=0.187, p=0.047, non-IPF: rs=0.320, p=0.001). However, baseline SUVmax and TBR were not associated with change in QoL in patients with IPF and non-IPF ILD over 4 years of follow-up. At 4 years post diagnosis, surviving patients with IPF reported declining QoL whereas improvement was seen in patients with ILD who did not have IPF.
目的:在本研究中,我们调查了FDG-PET/CT参数是否与ILD患者4年随访期间的生活质量(QoL)变化相关.
方法:患者在诊断时接受PET-CT成像,并使用圣乔治呼吸问卷(SGRQ)进行年度QoL评估,直至死亡或随访4年。根据SGRQ总体和子量表评分评估最大标准摄取值(SUVmax)和组织背景比(TBR)。
结果:193例患者(特发性肺纤维化(IPF)亚组94例,非IPF亚组99例)接受了基线FDG-PET/CT成像和QoL评估。在两个ILD亚组中,基线SUVmax和SGRQ评分之间观察到弱至中度相关性。在4年的随访中,基线SUVmax或TBR与SGRQ评分变化之间未观察到相关性。在IPF分组中,存活患者在诊断后4年报告QoL下降,而存活的非IPFILD患者QoL改善.
结论:在两个ILD亚组中观察到基线SUVmax和SGRQ评分之间的弱至中度正相关(IPF:rs=0.187,p=0.047,非IPF:rs=0.320,p=0.001)。然而,基线SUVmax和TBR与IPF和非IPFILD患者在4年随访期间的QoL变化无关。诊断后4年,存活的IPF患者报告QoL下降,而无IPF的ILD患者QoL改善.